Keyphrases
Parkinson's Disease
100%
Non-small Cell Lung Cancer (NSCLC)
76%
Tumor
67%
Older Adults
61%
Confidence Interval
60%
Heart Failure
55%
Alzheimer's Disease
53%
Escherichia Coli O157
44%
Lung Cancer
41%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
40%
Suprachiasmatic nucleus
37%
Cardiovascular Disease
37%
Breast Cancer
36%
United States
34%
Clinical Trials
34%
In Cancer
33%
Inflammation
32%
T Cells
32%
Virus
31%
Chemotherapy
31%
Circadian Rhythm
29%
Atypical Hemolytic Uremic Syndrome (aHUS)
29%
Overall Survival
29%
Randomized Controlled Trial
28%
Whole Genome
28%
Patients with Heart Failure
28%
Risk Factors
26%
Oxidative Stress
25%
Multiple Myeloma
25%
Pan-cancer Analysis
25%
Gene Expression
25%
Phase II Study
25%
Older Patients
24%
Diarrhea
24%
Obesity
24%
Gait
24%
Coronary Artery Disease
23%
Meta-analysis
23%
Quality of Life
23%
Elderly Patients
23%
Phase II Trial
22%
Autosomal Dominant Alzheimer's Disease
22%
Bone Marrow
21%
Hazard Ratio
21%
Shiga Toxin-producing Escherichia Coli
21%
Hypertension
21%
COVID-19
21%
Chimeric Antigen Receptor T Cells (CAR-T)
21%
Natural Killer Cells
20%
High Risk
20%
Clinical Outcomes
19%
Mouse Model
19%
NF-B
19%
Placebo
19%
Diabetes
19%
Osteoclast
19%
Escherichia Coli
18%
Carboplatin
18%
Asthma
18%
Upper Extremity
18%
Graft-versus-host Disease (GvHD)
18%
Targeted Therapy
18%
Daily Rhythm
17%
Small Intestine
17%
Triple-negative Breast Cancer
17%
Cerebrospinal Fluid
17%
Integrin
17%
Intrinsically Disordered Proteins
17%
Acute Myeloid Leukemia
17%
Acute Myocardial Infarction
17%
Stool
16%
Functional Magnetic Resonance Imaging
16%
Odds Ratio
16%
Blood Pressure
16%
Cancer Types
16%
Hospitalization
16%
Human Cancer
16%
Adaptation
16%
Docetaxel
16%
Bone Metastasis
16%
Tumor Cells
16%
Cancer Genome Atlas
15%
B Cells
15%
Congestive Heart Failure
15%
Interleukin-1β
15%
Apoptosis
15%
Functional Connectivity
15%
Positron Emission Tomography
15%
Astrocytes
15%
Tumor Growth
15%
Interferon-stimulated Gene 15 (ISG15)
15%
Post-stroke
15%
Left Ventricular Function
14%
Macrophages
14%
Whole Genome Sequencing
14%
Pemetrexed
14%
Acute Gastroenteritis
14%
Comorbidity
14%
Disease Progression
14%
Circadian Clock
14%
Medicine and Dentistry
Diseases
96%
Neoplasm
87%
Congestive Heart Failure
71%
Malignant Neoplasm
71%
Non Small Cell Lung Cancer
65%
Breast Cancer
60%
Lung Cancer
43%
Infection
38%
Cardiovascular Disease
37%
Gut
31%
Cardiovascular System
31%
Clinician
29%
T Cell
29%
Pediatrics
28%
Clinical Trial
27%
Biological Marker
26%
Cancer
26%
Atypical Hemolytic Uremic Syndrome
25%
Overall Survival
24%
Alzheimer's Disease
24%
Metastatic Carcinoma
24%
Diagnosis
23%
Surgery
23%
Prevalence
22%
Emergency Department
22%
Immunotherapy
21%
Apoplexy
21%
Randomized Controlled Trial
21%
Pathogen
20%
Parkinson's Disease
20%
Quality of Life
20%
Multiple Myeloma
20%
Diarrhea
20%
Systematic Review
19%
COVID-19
19%
Diabetes
19%
In Vitro
19%
Meta-Analysis
19%
Human Immunodeficiency Virus
18%
Messenger RNA
18%
Escherichia Coli O157
18%
Health Care Cost
18%
Asthma
17%
B Cell
17%
Bone Metastasis
17%
Arm
16%
Lung
16%
Small Cell Lung Cancer
16%
Positron Emission Tomography
16%
Elderly Patient
16%
Adverse Event
15%
Immunity
15%
Gene Expression
15%
Medicine
15%
Placebo
14%
Targeted Therapy
14%
Cohort Analysis
14%
Recurrent Disease
14%
Tumor Progression
14%
Shiga Toxin Producing Escherichia Coli
14%
Melanoma
14%
Odds Ratio
14%
Comorbidity
13%
Hematopoietic Cell
13%
Osteoclast
13%
Acute Heart Infarction
13%
Epidermal Growth Factor Receptor
13%
Radiation Therapy
13%
Acute Gastroenteritis
12%
Receptor
12%
Acute Myeloid Leukemia
12%
Triple Negative Breast Cancer
12%
Outpatient
12%
Mental Health
12%
Cohort Effect
12%
Oncology
12%
Geriatrics
12%
Hazard Ratio
12%
Colorectal Carcinoma
11%
Diabetes Mellitus
11%
Integrin
11%
Cancer Risk
11%
Biopsy Technique
11%
Adolescence
11%
Chimeric Antigen Receptor T-Cell
11%
Prostate Cancer
11%
Tumor Cell
11%
Osteolysis
11%
Neoadjuvant Chemotherapy
11%
Macrophage
11%
Body Mass Index
11%
Natural Killer Cell
10%
Diastolic Function
10%
Cytokine
10%
Stem Cell
10%
Upper Limb
10%
Virus
10%
Dermatological Agent
10%
Pemetrexed
10%
Randomized Clinical Trial
10%